Research programme: cancer therapies - Cetek

Drug Profile

Research programme: cancer therapies - Cetek

Alternative Names: CTK 000147; CTK 100144; CTK 110

Latest Information Update: 11 Dec 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cetek Corporation
  • Class Small molecules
  • Mechanism of Action Aurora kinase inhibitors; HSP90 heat-shock protein inhibitors; Proteasome inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 05 Dec 2007 Advanced Viral Research Corp. acquires certain assets originally owned by Cetek Corporation
  • 20 Jul 2007 This programme is still in active development
  • 22 Jun 2005 Preclinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top